Millennium Management’s Neurocrine Biosciences NBIX Stock Holding History

Millennium Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-46,600	Closed	-$5.15M	–	6180
2025 Q1	$5.15M	Buy	46,600 +39,500	+556%	+$5M	﹤0.01%	2831
2024 Q4	$969K	Buy	+7,100	New	+$878K	﹤0.01%	4224
2024 Q3	–	Sell	-107,500	Closed	-$14.8M	–	6347
2024 Q2	$14.8M	Buy	+107,500	New	+$14.7M	0.01%	1751
2022 Q1	–	Sell	-60,000	Closed	-$5.11M	–	7278
2021 Q4	$5.11M	Sell	60,000 -73,700	-55%	-$6.78M	﹤0.01%	2888
2021 Q3	$12.8M	Sell	133,700 -16,300	-11%	-$1.54M	0.01%	1763
2021 Q2	$14.6M	Hold	150,000	–	–	0.01%	1500
2021 Q1	$14.6M	Buy	150,000 +138,800	+1,239%	+$14.6M	0.01%	1396
2020 Q4	$1.07M	Buy	+11,200	New	+$1.08M	﹤0.01%	3695
2019 Q3	–	Sell	-50,000	Closed	-$4.22M	–	4424
2019 Q2	$4.22M	Hold	50,000	–	–	0.01%	1909
2019 Q1	$4.41M	Buy	+50,000	New	+$4.18M	0.01%	1862
2017 Q1	–	Sell	-80,000	Closed	-$3.1M	–	3724
2016 Q4	$3.1M	Buy	80,000 +30,000	+60%	+$1.36M	0.01%	1638
2016 Q3	$2.53M	Hold	50,000	–	–	﹤0.01%	1799
2016 Q2	$2.27M	Buy	+50,000	New	+$2.3M	0.01%	1718
2015 Q4	–	Sell	-500,000	Closed	-$19.9M	–	3662
2015 Q3	$19.9M	Buy	500,000 +200,000	+67%	+$9.67M	0.04%	567
2015 Q2	$14.3M	Buy	+300,000	New	+$12.7M	0.03%	776
2013 Q4	–	Sell	-75,400	Closed	-$854K	–	3655
2013 Q3	$854K	Sell	75,400 -14,900	-17%	-$205K	﹤0.01%	2215
2013 Q2	$1.21M	Buy	+90,300	New	+$1.11M	﹤0.01%	1871

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's NBIX Position: Q1 2026 in Review

Millennium Management increased its Neurocrine Biosciences (NBIX) stake by 182% in Q1 2026, buying an estimated $107M and bringing the position to 1,247,447 shares worth $164M. The position accounts for 0.07% of the portfolio, ranked #263.

Millennium Management first reported a position in NBIX in Q2 2013 and has held it in 48 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Millennium Management held 1,247,447 shares of Neurocrine Biosciences worth $164M as of Q1 2026.
Millennium Management bought 804,581 Neurocrine Biosciences shares in Q1 2026, an estimated $107M.
Neurocrine Biosciences made up 0.07% of Millennium Management's portfolio in Q1 2026, its #263 holding.
Millennium Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 48 quarters since.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.